Overview
Elagolix is a first-in-class oral GnRH antagonist developed for the management of endometriosis-related pain. It works by selectively blocking pituitary GnRH receptors, reducing estrogen production and suppressing endometrial tissue growth. Approved by the FDA in 2018, it offers a non-surgical alternative for patients with moderate to severe symptoms. Unlike traditional GnRH agonists, elagolix provides dose-dependent estrogen suppression without an initial flare-up effect. Its chemical structure features a unique heterocyclic core optimized for oral bioavailability and receptor specificity. The drug is typically administered as a sodium salt formulation to enhance solubility.
Physical and Chemical Properties
Elagolix is a synthetic small molecule with a molecular weight of 601.53 g/mol. The crystalline powder exhibits stability under recommended storage conditions but may degrade upon prolonged exposure to light or moisture. Its solubility profile favors organic solvents like dimethyl sulfoxide (DMSO), while aqueous solubility is limited—a factor considered in formulation development. Spectroscopic characterization shows characteristic peaks in NMR and mass spectrometry consistent with its chloro-substituted aromatic rings and amide linkages. The compound's pKa and logP values contribute to its absorption and distribution properties, enabling effective crossing of biological barriers while maintaining target engagement.
Main Applications
The primary application of elagolix is in treating pain associated with endometriosis, a condition affecting approximately 10% of reproductive-age women. Clinical trials demonstrated significant reduction in dysmenorrhea and non-menstrual pelvic pain at daily doses of 150mg (once daily) and 200mg (twice daily). Emerging research explores its potential in uterine fibroids and assisted reproductive technologies where controlled ovarian suppression is beneficial. Off-label use requires careful risk-benefit assessment due to its hypoestrogenic effects. Combination therapies with add-back hormone regimens are being investigated to mitigate bone mineral density concerns during long-term use.
Safety and Storage
Elagolix carries a boxed warning for bone loss, with recommendations limiting continuous use to 24 months without add-back therapy. Common adverse effects include hot flashes (35% incidence), headache, and nausea. Laboratory monitoring of liver enzymes and lipid profiles is advised during treatment. For bulk handling, use NIOSH-approved respirators and nitrile gloves when handling powder form. Store in original containers under refrigerated conditions (2-8°C) with desiccants. Avoid freezing or exposure to temperatures above 30°C. Shelf life typically exceeds 24 months when stored properly, though batch-specific certificates should always be verified.
B2B Procurement Guide
Pharmaceutical manufacturers sourcing elagolix should prioritize suppliers with: 1) Active Pharmaceutical Ingredient (API) registration in target markets (e.g., US DMF, EU CEP), 2) ISO 13485 or equivalent certification for hormonal products, and 3) validated analytical methods for impurity profiling. Request comprehensive documentation including residual solvent analysis, polymorph characterization, and genotoxic impurity testing. For clinical trial materials, ensure suppliers can provide GMP batches with complete chain-of-custody records. Negotiate tiered pricing for annual volume commitments above 10kg. Customs clearance may require special permits for controlled substance analogs in some jurisdictions.
Related Manufacturers
- 主营：莪术二酮、人参皂苷rc
- 主营：甘氨酸、海藻糖、钙钛矿、氟苯基、油胺碘、硅酸锆、甘油醚、青霉素、状结晶、酒石酸、抗氧剂、钛白粉、凉味剂、晶粉末、硫酸钯、苯乙酮、白色粉、中间体、山梨醇、淡奶油、2-[[(3ar、2-氯烟酸、聚氯乙烯、清澈液体、白色细粉
- 主营：古龙酸、6-疏基瞟呤、紫草素、恶拉戈利、6-氯嘌呤、菲啰嗪一钠盐、6-二氟-4-羟基苯腈
- 主营：1689-89-0、酒石酸、61438-64-0、恶拉戈利钠832720、81810-66-4、17316-67-5、31430-15-6、68786-66-3、42461-84-7、115550-35-1、217500-96-4、101831-37-2、129496-10-2、沃尼妙林、丹诺沙星、非泼罗尼、加米霉素、能霉素钠、达氟沙星、奥苯达唑、粘杆菌素、双氢链霉素、酸泰妙菌素、盐酸四咪唑、盐酸沙拉沙星
- 主营：恶拉戈利钠、生物化工试剂、中间体、帕罗韦德中间体
- 主营：间苯二甲胺、4-叔丁基苯基硼酸、硫化砷、恶拉戈利钠盐832720、808洗涤剂胰加漂T、N-二甲基乙二胺、增甘膦、N-甲基烟酰胺、富马酸、霜脲氰、顺式-2、6-二甲基、氧化铋、三甲氧基硅烷、紫外线吸收剂、八钼酸铵、4'-二羟基二苯、十二烷基苯磺酸钠、聚乙烯醇、邻苯二甲酸丁苄酯、甲基环戊烯醇酮、1-硫代甘油、己二酸双(2-丁氧基